Linked Life Data

15958587

Source:http://linkedlifedata.com/resource/pubmed/id/15958587

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15958587rdf:typepubmed:Citationlld:pubmed
pubmed-article:15958587lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:15958587lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:15958587lifeskim:mentionsumls-concept:C0593802lld:lifeskim
pubmed-article:15958587lifeskim:mentionsumls-concept:C0752312lld:lifeskim
pubmed-article:15958587lifeskim:mentionsumls-concept:C0246421lld:lifeskim
pubmed-article:15958587lifeskim:mentionsumls-concept:C0520484lld:lifeskim
pubmed-article:15958587lifeskim:mentionsumls-concept:C0439590lld:lifeskim
pubmed-article:15958587lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:15958587pubmed:issue12lld:pubmed
pubmed-article:15958587pubmed:dateCreated2005-6-16lld:pubmed
pubmed-article:15958587pubmed:abstractTextOvariectomized mice bearing tumor xenografts grown from aromatase-transfected estrogen receptor (ER)-positive human breast cancer cells (MCF-7Ca) were injected s.c. with 10 microg/d letrozole for up to 56 weeks. Western blot analysis of the tumors revealed that ERs (ERalpha) were increased at 4 weeks but decreased at weeks 28 and 56. Expression of erbB-2 and p-Shc increased throughout treatment, whereas growth factor receptor binding protein 2 (Grb2) increased only in tumors proliferating on letrozole (weeks 28 and 56). In cells isolated from tumors after 56 weeks and maintained as a cell line (LTLT-Ca) in 1 micromol/L letrozole, ERalpha was also decreased whereas erbB-2, adapter proteins (p-Shc and Grb2), and the signaling proteins in the mitogen-activated protein kinase (MAPK) cascade were increased compared with MCF-7Ca cells. Growth was inhibited in LTLT-Ca cells but not in MCF-7Ca cells treated with MAPK kinase 1/2 inhibitors U0126, and PD98059 (IC(50) approximately 25 micromol/L). PD98059 (5 micromol/L) also reduced MAPK activity and increased ERalpha to the levels in MCF-7Ca cells. Epidermal growth factor receptor kinase inhibitor, gefitinib (ZD1839) inhibited growth of LTLT-Ca cells (IC(50) approximately 10 micromol/L) and restored their sensitivity to tamoxifen and anastrozole. In xenografts, combined treatment with ER down-regulator fulvestrant and letrozole, prevented increases in erbB-2 and activation of MAPK and was highly effective in inhibiting tumor growth throughout 29 weeks of treatment. These results indicate that blocking both ER- and growth factor-mediated transcription resulted in the most effective inhibition of growth of ER-positive breast cancer cells.lld:pubmed
pubmed-article:15958587pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15958587pubmed:languageenglld:pubmed
pubmed-article:15958587pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15958587pubmed:citationSubsetIMlld:pubmed
pubmed-article:15958587pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15958587pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15958587pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15958587pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15958587pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15958587pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15958587pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15958587pubmed:statusMEDLINElld:pubmed
pubmed-article:15958587pubmed:monthJunlld:pubmed
pubmed-article:15958587pubmed:issn0008-5472lld:pubmed
pubmed-article:15958587pubmed:authorpubmed-author:LongBrian JBJlld:pubmed
pubmed-article:15958587pubmed:authorpubmed-author:JelovacDanije...lld:pubmed
pubmed-article:15958587pubmed:authorpubmed-author:GoloubevaOlga...lld:pubmed
pubmed-article:15958587pubmed:authorpubmed-author:BrodieAngela...lld:pubmed
pubmed-article:15958587pubmed:authorpubmed-author:MacedoLuciana...lld:pubmed
pubmed-article:15958587pubmed:authorpubmed-author:SabnisGauriGlld:pubmed
pubmed-article:15958587pubmed:issnTypePrintlld:pubmed
pubmed-article:15958587pubmed:day15lld:pubmed
pubmed-article:15958587pubmed:volume65lld:pubmed
pubmed-article:15958587pubmed:ownerNLMlld:pubmed
pubmed-article:15958587pubmed:authorsCompleteYlld:pubmed
pubmed-article:15958587pubmed:pagination5380-9lld:pubmed
pubmed-article:15958587pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:meshHeadingpubmed-meshheading:15958587...lld:pubmed
pubmed-article:15958587pubmed:year2005lld:pubmed
pubmed-article:15958587pubmed:articleTitleActivation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.lld:pubmed
pubmed-article:15958587pubmed:affiliationDepartment of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.lld:pubmed
pubmed-article:15958587pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15958587pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15958587pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15958587lld:pubmed